September 26, 2023 12:48 PM EDTUpdated 05:21 PM

Bristol Myers joins AstraZeneca in agreeing to drug price negotiation terms ahead of first deadline

Zachary Brennan

Senior Editor

Nicole DeFeudis

Editor

Pharma companies are now reluctantly agreeing to participate in the Center for Medicare and Medicaid Services’ first round of negotiations for 10 drugs.

Ahead of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers joins AstraZeneca in agreeing to drug price negotiation terms ahead of first deadline

Zachary Brennan

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Bris­tol My­ers joins As­traZeneca in agree­ing to drug price ne­go­ti­a­tion terms ahead of first dead­line

Senior Editor

Editor

Sign up to read this article for free.

Bristol Myers joins AstraZeneca in agreeing to drug price negotiation terms ahead of first deadline